← Back to patent-cliff list
Reboxetine (Axsome Therapeutics)
Tier C — Watch / tradeReboxetine (Axsome Therapeutics)
Axsome Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NET
Indications (approved)：发作性睡病, 猝倒症, 过度嗜睡, Obstructive sleep apnoea syndrome
Regional status
US
Phase III
2021-09-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Reboxetine (Axsome Therapeutics)?
Approved indications include: 发作性睡病, 猝倒症, 过度嗜睡, Obstructive sleep apnoea syndrome.
When does the Reboxetine (Axsome Therapeutics) patent expire?
No public expiry year is available for Reboxetine (Axsome Therapeutics) yet; this page updates once verified.
How do I get a quote for Reboxetine (Axsome Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06